Effect of N -Acetylcysteine in treatment of hemodialysis patients
Phase 2
- Conditions
- Renal failureHemodialysis patients.
- Registration Number
- IRCT2014051917757N1
- Lead Sponsor
- Vice Chancellor for Development, Research and Technology of Ahvaz Jondishapour University of Medica
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 78
Inclusion Criteria
All of the chronic hemodialysis patients due to end stage renal disease more than 16 years old and at least three months has been past from starting of hemodialysis.
Exclusion criteria:
Every acute disease leads to hospitalization from one month before or during trial
; Allergy to N-acetylcysteine; Hepatic cirrhosis; Using vitamin E or C or every known antioxidant from 2 weeks before or during trial; Congestive heart failure or ejection fraction less than 35%; Not using of N- acetylcysteine or placebo more than 20% of total drug.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hemoglobin. Timepoint: Before intervention and 6 weeks after intervention. Method of measurement: by cyanmet hb method as gr/dl with drabkin kit.;Hematocrit. Timepoint: Before intervention and 6 weeks after intervention. Method of measurement: By Santrifiuj micro hematocrit as persentage.
- Secondary Outcome Measures
Name Time Method